George L Chen
Overview
Explore the profile of George L Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
564
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamilton B, Onstad L, Carpenter P, Pidala J, Jurdi N, Farhadfar N, et al.
Contemp Clin Trials
. 2024 Jul;
145:107637.
PMID: 39038701
Background: Chronic graft-versus-host disease (GVHD) is a leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation. Despite significant progress in chronic GVHD therapies, challenges remain in understanding...
2.
Pidala J, Onstad L, Baumrin E, Carpenter P, Cutler C, Arai S, et al.
Blood Adv
. 2024 Jun;
8(17):4651-4657.
PMID: 38885484
Cutaneous sclerosis, a highly morbid subtype of chronic graft-versus-host disease (GVHD), demonstrates limited treatment response under current National Institutes of Health (NIH) response measures. We explored novel sclerosis-specific response measures...
3.
Pidala J, Carpenter P, Onstad L, Pavletic S, Hamilton B, Chen G, et al.
PLoS One
. 2024 May;
19(5):e0298026.
PMID: 38753616
Chronic graft-versus-host disease (GVHD) is an immune-mediated disorder that causes significant late morbidity and mortality following allogeneic hematopoietic cell transplantation. The "Close Assessment and Testing for Chronic GVHD (CATCH)" study...
4.
McCarthy P, Attwood K, Liu X, Chen G, Minderman H, Alousi A, et al.
Bone Marrow Transplant
. 2023 Dec;
59(3):334-343.
PMID: 38110620
Identifying plasma biomarkers early after allo-HCT may become crucial to prevent and treat severe aGvHD. We utilized samples from 203 allo-HCT patients selected from the Blood & Marrow Transplant Clinical...
5.
Chen G, Shpall E
J Clin Invest
. 2023 May;
133(10).
PMID: 37183817
Cytomegalovirus (CMV) viremia from reactivation of latent infection is a common complication after allogeneic hematopoietic cell transplantation (HCT). Untreated, CMV viremia can progress to affect other organs, resulting in organ...
6.
Elshoury A, Maguire O, Conway A, Tario J, Soh K, Ross M, et al.
Transplant Cell Ther
. 2022 Nov;
29(2):112.e1-112.e9.
PMID: 36436782
Hypoxic conditions preserve the multipotency and self-renewing capacity of murine bone marrow and human cord blood stem cells. Blood samples stored in sealed blood gas tubes become hypoxic as leukocytes...
7.
Chen G, Onstad L, Martin P, Carpenter P, Pidala J, Arai S, et al.
Haematologica
. 2022 May;
108(2):483-489.
PMID: 35615925
Successful treatment of chronic graft-versus-host disease (GvHD) often requires long-term systemic therapy (ST). Durable discontinuation of ST reflects the resolution of active chronic GvHD. We evaluated the factors associated with...
8.
Merz A, Merz M, Zhang Y, Stecklein K, Pleskow J, Chen G, et al.
Transplant Cell Ther
. 2021 Oct;
27(3):245.e1-245.e8.
PMID: 34706824
Revaccination after autologous hematopoietic cell transplantation (AHCT) is recommended in post-HCT survivorship guidelines to restore humoral immunity. Data on seroconversion after AHCT and vaccination in multiple myeloma (MM) patients are...
9.
Pidala J, Onstad L, Martin P, Hamilton B, Cutler C, Kitko C, et al.
Blood Adv
. 2021 Sep;
5(22):4549-4559.
PMID: 34535015
Prior clinical trials largely considered prednisone 1 mg/kg per day with or without calcineurin inhibitor as standard initial therapy for chronic graft-versus-host disease (cGVHD), but uncertainty remains regarding the extent...
10.
DeFilipp Z, Alousi A, Pidala J, Carpenter P, Onstad L, Arai S, et al.
Blood Adv
. 2021 Sep;
5(20):4278-4284.
PMID: 34521116
Chronic graft-versus-host disease (cGVHD) is the leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation. To better understand patients at highest risk for nonrelapse mortality (NRM), we...